Maze Therapeutics, Inc. (MAZE)
Automate Your Wheel Strategy on MAZE
With Tiblio's Option Bot, you can configure your own wheel strategy including MAZE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MAZE
- Rev/Share 0.0
- Book/Share 8.2883
- PB 4.5365
- Debt/Equity 0.0637
- CurrentRatio 17.6964
- ROIC -0.3318
- MktCap 1809243794.0
- FreeCF/Share -2.3597
- PFCF -16.7481
- PE -13.647
- Debt/Assets 0.0573
- DivYield 0
- ROE -0.4462
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MAZE | Raymond James | -- | Outperform | -- | -- | Nov. 14, 2025 |
| Initiation | MAZE | BTIG Research | -- | Buy | -- | $30 | Sept. 2, 2025 |
| Initiation | MAZE | H.C. Wainwright | -- | Buy | -- | $34 | July 23, 2025 |
| Initiation | MAZE | Wedbush | -- | Outperform | -- | $17 | July 8, 2025 |
News
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript
Published: November 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Maze Therapeutics, Inc. ( MAZE ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:00 AM EST Company Participants Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma.
Read More
National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry. Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry.
Read More
About Maze Therapeutics, Inc. (MAZE)
- IPO Date 2025-01-31
- Website https://www.mazetx.com
- Industry Biotechnology
- CEO Jason V. Coloma M.P.H.,
- Employees 125